Cannabis Clinical Trial
Official title:
Behavioral Pharmacology of Cannabis and Nicotine
Verified date | March 2024 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the individual and interactive pharmacokinetic and pharmacodynamic effects of smoked cannabis and nicotine.
Status | Completed |
Enrollment | 26 |
Est. completion date | August 31, 2023 |
Est. primary completion date | July 24, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Have provided written informed consent - Be between the ages of 18 and 55 - Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests - Test negative for drugs of abuse aside from cannabis (via urine sample) and alcohol (via breath sample) at the screening visit and upon arrival for each experimental session. - Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission. - Have a body mass index (BMI) in the range of 18 to 36 kg/m2 - Blood pressure at screening visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg - Have not donated blood in the prior 30 days. - Report prior experience inhaling cannabis. - Report using cannabis at least 5 times in the past year. - Smoke =5 tobacco cigarettes per day on average in the past month. - Use an e-cigarette at least 15 of the past 30 days. - Have a breath carbon monoxide (CO) of >8ppm or urine cotinine >200ng/mL to confirm current nicotine use status. Exclusion Criteria: - Non-medical use of psychoactive drugs (aside from cannabis) other than, nicotine, alcohol, or caffeine in the month prior to the Screening Visit; - History of or current evidence of significant medical or psychiatric illness which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the subject. - Use of an over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the subject. - Use of a prescription medication (with the exception of birth control prescriptions) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the subject. - History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina). - Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing. - Epilepsy or a history of seizures. - Individuals who have a recent history of traumatic brain injury diagnosed by CT/MRI and have current sequela from prior brain injury, as determined by the study physician - Individuals with anemia. - Prior history of allergic or serious adverse reaction to either cannabis or tobacco/nicotine. - Average use of cannabis more than 2 times per week in the prior 3 months. |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Amount of Nicotine (mL of Smoke/Vapor) Inhaled | Amount of nicotine used (determined by total volume (mL) of cigarette smoke or JUUL vapor inhaled) after cannabis exposure in each session. | 0-5 hours | |
Secondary | Mean Peak Change From Baseline Self-reported Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ) | Mean Peak Change From Baseline rating (0-100) of Drug Effect on the DEQ, with 0 being no effect and 100 being maximum effect. | 0-5 hours | |
Secondary | Mean Peak Change From Baseline Psychomotor Performance as Assessed by the Digit Symbol Substitution Task (DSST) | Computerized version of Digit Symbol Substitution Task will be administered to assess psychomotor performance. Total correct trials in 90-seconds. Minimum score of 0 but no maximum score (higher scores indicate better performance). | 0-5 hours | |
Secondary | Mean Peak Change From Baseline Working Memory Performance as Assessed by the Paced Auditory Serial Addition Task (PASAT) | Computerized version of Paced Auditory Serial Addition Task will be administered to assess working memory performance. Total correct trials out of 90 recorded is primary outcome (higher scores indicate better performance). | 0-5 hours | |
Secondary | Mean Peak Change From Baseline Behavioral Task Performance as Assessed by the DRUID App | Behavioral task performance will be assessed with the DRUID app's Global impairment score (range 0-100), where lower scores indicate better performance. | 0-5 hours | |
Secondary | Mean Peak Change From Baseline Tobacco Craving as Assessed by the Tobacco Craving Questionnaire | Mean peak change from baseline rating (0-100) of "Craving" with 0 being no craving and 100 being maximum craving. | 0-5 hours | |
Secondary | Mean Peak Change From Baseline Cannabis Craving as Assessed by the Cannabis Craving Questionnaire | Mean peak change from baseline rating (0-100) of "Craving" with 0 being no craving and 100 being maximum craving | 0-5 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04199468 -
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
|
Phase 1 | |
Completed |
NCT04587700 -
Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery
|
||
Not yet recruiting |
NCT05899946 -
An Integrated Program to Promote Anti-cannabis Messages
|
N/A | |
Active, not recruiting |
NCT02735954 -
Colorado Marijuana Users Health Cohort
|
||
Completed |
NCT00842985 -
Dronabinol Interactions in Humans
|
N/A | |
Active, not recruiting |
NCT04693884 -
Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise
|
Early Phase 1 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Active, not recruiting |
NCT03560934 -
Tetrahydrocannabinol (THC) and Sleep
|
Early Phase 1 | |
Recruiting |
NCT04704271 -
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
|
Phase 1 | |
Withdrawn |
NCT03245658 -
The Effect of Cannabis in Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT04911127 -
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
|
Phase 1 | |
Not yet recruiting |
NCT05999383 -
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
|
Phase 2 | |
Recruiting |
NCT04429568 -
THC Crossover Study
|
N/A | |
Completed |
NCT05554146 -
Pain Inflammation and Cannabis in HIV
|
N/A | |
Not yet recruiting |
NCT05320367 -
A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users
|
Phase 1/Phase 2 | |
Terminated |
NCT03251326 -
Nabilone in Cannabis Users With PTSD
|
Phase 1/Phase 2 | |
Completed |
NCT02567344 -
Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving
|
N/A | |
Completed |
NCT00176085 -
Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH
|
Phase 1 | |
Enrolling by invitation |
NCT06235632 -
Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers
|
N/A |